Servier is a pharmaceutical company focused on cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, neurodegenerative diseases, and generic drugs. Of that list, the company's primary source of revenue comes from cardiovascular diseases, and Servier is investing about 25% of its $5 billion revenue back into R&D for future drug development, in areas like heart failure in particular. As such, any improvements to this R&D process – whether it is on new dosage combinations or new molecular entities – has a large established base upon which to make a difference. The help drive such improvements, Servier partnered with Numerate, a startup that uses machine learning to design drug-like molecules for hard-to-target diseases.
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)